16D0 Lu, Bo - Thomas Jefferson University - Thomas Jefferson University
bxl017

Bo Lu, MD

Contact Dr. Lu

G-301 Bodine Cancer Center
111 S. 11th Street
Philadelphia, PA 19107

(215) 955-6705
(215) 503-0013 fax

Most Recent Peer-reviewed Publications

  1. A method of detecting sea fogs using CALIOP data and its application to improve MODIS-based sea fog detection
  2. A method of surface marker location optimization for tumor motion estimation in lung stereotactic body radiation therapy
  3. Serum clusterin as a tumor marker and prognostic factor for patients with esophageal cancer
  4. Ghost marker detection and elimination in marker-based optical tracking systems for real-time tracking in stereotactic body radiotherapy
  5. Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests
  6. A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect
  7. Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer
  8. Prevention of gross setup errors in radiotherapy with an efficient automatic patient safety system
  9. Prev 13D4 ention of gross setup errors in radiotherapy with an efficient automatic patient safety system.
  10. A further investigation of the centroid-to-centroid method for stereotactic lung radiotherapy: A phantom study
  11. Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab
  12. PM02734 (Elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase (Clinical Cancer Research (2011))
  13. A study of IMRT planning parameters on planning efficiency, delivery efficiency, and plan quality
  14. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy
  15. ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma
  16. ALK inhibitor PF02341066 (Crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK
  17. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1
  18. A patient alignment solution for lung SBRT setups based on a deformable registration technique
  19. Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects
  20. Molecular profiling to optimize treatment in non-small cell lung cancer: A review of potential molecular targets for radiation therapy by the translational research program of the Radiation Therapy Oncology Group
0